Page 244 - 2022_01-Haematologica-web

C. Pawlyn et al.
A
B
Figure 1. Outcomes of patients of different ages undergoing autologous stem cell transplantation. (A, B) Progression-free survival (A) and overall survival (B) of patients in the groups aged <65 years (blue), 65-69 years (red) and 70-75 years (yellow). PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval.
noASCT or TNE), ASCT was associated with a significant improvement in PFS (ASCT vs. noASCT: HR=0.41, P<0.0001) (Figure 2D). The same benefit was seen in terms of OS: TE-ASCT median 84.1 months, TE-noASCT 50.9 months, TNE 60.2 months (Figure 2C) (ASCT vs. noASCT: HR=0.51, P<0.0001) (Figure 2E). The benefit of ASCT was independent of the subsequent use of mainte-
nance therapy, with longer PFS and OS seen in the TE- ASCT group than in the TNE group whether patients were randomized to observation or maintenance therapy (Online Supplementary Figure S5).
Where possible a frailty-surrogate score was derived for patients in each of the age-matched groups using the UK Myeloma Research Alliance Risk Profile (MRP)17 (Table 2).
236
haematologica | 2022; 107(1)